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NUTRITIONAL SUPPORT: A SURVEY OF PEDIATRIC BLOOD AND MAR-
ROW TRANSPLANT CONSORTIUM INSTITUTIONS
Olson, E.A.1, Fisher, V.L.2, Barnes, Y.J.3, Skeens, M.A.4, Niess, D.5
1Children’s Healthcare of Atlanta, AFLAC Cancer Center & Blood
Disorder Service, Emory University Department of Pediatrics, Atlanta,
GA; 2Rainbow Babies and Children’s Hospital, Ireland Cancer Center,
Cleveland, OH; 3St Louis Children’s Hospital, St. Louis, MO; 4Colum-
bus Children’s Hospital, Columbus, OH; 5Children’s Hospitals of Min-
nesota, Minneapolis, MN.
Purpose: This survey was designed to identify the nutritional
practices used for the pediatric blood and marrow transplant
(BMT) patient by institutions within the Pediatric Blood and
Marrow Transplant Consortium (PBMTC). A secondary aim is to
develop a standard of care for nutritional support for the pediatric
BMT patient.
Methods: A survey was distributed to member institutions at the
semi-annual PBMTC meeting. The survey was designed to collect
information about institutional demographics, transplant speciﬁc
nutritional practices, and supportive care.
Results: Seventy-eight percent of the surveys were returned.
Both allogeneic and autologous transplant procedures were per-
formed at 94% of the institutions. The majority of institutions used
total body irradiation (TBI) in at least 25% of the conditioning
regimens. There were no nutritional practice differences between
myeloablative and non myeloablative transplants. Seventy-ﬁve per-
cent of centers reported using mucositis prophylaxis, the majority
utilized glutamine (40%) and/or trophic feeds (28%). At some
point during the transplant course, ninety-four percent of institu-
tions still reported using hyperalimentation. Parental nutrition was
not used at two institutions. Two thirds of the centers utilized
continuous nasogastric (NG) feeds. Ninty percent of institutions
employed oral supplementation in patients with chronic graft ver-
sus host disease, while approximately half of the institutions also
used enteral feeding. Various methods were used to control nausea,
vomiting, diarrhea, and gastric paresis. Education was provided by
inservice at 47% of the institutions. At time of discharge, multiple
nutritional supplements were prescribed.
Conclusion: Based on the submitted surveys, the PBMTC in-
stitutions employ various nutritional support practices. These ﬁnd-
ings suggest a need to develop a nutritional support standard of
care for the pediatric BMT patient. Further exploration of prac-
tices and outcomes is needed to expand evidence based nutritional
practices in the pediatric BMT patient.
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POST TRANSPLANT AUTOIMMUNE HEMOLYTIC ANEMIA AND OTHER
CYTOPENIAS ARE INCREASED IN YOUNG BABIES UNDERGOING UNRE-
LATED DONOR UMBILICAL CORD BLOOD TRANSPLANTATION
Page, K.M.1, Wood, S.1, Prasad, V.1, Szabolcs, P.1, Kurtzberg, J.1
1Duke University Medical Center, Durham, NC.
Unrelated donor umbilical cord blood transplantation (UCBT)
has shown great promise in the treatment of young babies with
early infantile, lysosomal storage diseases, hemoglobinopathies and
congenital bone marrow failure disorders. When a family history
of the disorder is present, subsequent affected babies can be diag-
nosed prenatally or at birth and transplanted in the ﬁrst 1-2 months
of life. Over the past 9 years, we have treated 16 neonates with
Krabbe disease (n9) metachromatic leukodystrophy (n1), Tay
Sachs disease (n1), Hurler syndrome (n2), Hunter syndrome
(n2) and beta thalassemia major (n1) with UCBT after myeloa-
blative conditioning therapy with Busulfan, Cyclophosphamide
and ATG. All babies received cyclosporine and methylprednisone
(n11) or cyclosporine  cellcept (n5) for prophylaxis against
GvHD which was continued at full dose for 6-9 months and then
weaned. All babies recieved high nucleated cell doses
(1010e7cells/kg) from their single cord blood unit. All but one
baby with Hunter syndrome maintained full donor chimerism.
Three patients died post transplant, 1 neonate with Krabbe of
persistant pulmonary hypertension in the ﬁrst 2 weeks post trans-
plant, 1 with Hunters who was a mixed chimera and died of
sequelae of chronic GvHD at 2 years of age and 1 with Tay Sachs
of sudden, unknown causes at 5 years of age. 57% of patients (8/14)
developed autoimmune hemolytic anemia alone or with thrombo-
cytopenia and neutropenia within the ﬁrst year post transplant in
the absence of signs of acute or chronic GvHD. All patients
responded to treatment with methylprednisolone, imuran /- rit-
uxan. Rapid withdrawal of cyclosporine was successful in all but 2
patients who broke through with evidence of chronic skin GvHD
controlled with FK-506. The high incidence of autoimmune dis-
ease post UCBT is unique to this population of very young babies.
Older children have been estimated to have a 4% chance of devel-
oping AHA. We hypothesize that pre and post transplant immu-
nosuppression interferes with the normal development of the im-
mune system in the ﬁrst year of life creating immune dysregulation
and graft directed cell destruction. After lytic agents to stabilize
disease, removal of chronic immunosuppressive therapy facilitates
resolution of the problem. Alternative strategies to prevent GvHD
should be developed for this unique patient population.
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OUTCOMES OF MATCHED RELATED DONOR BONE MARROW TRANS-
PLANTATION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYN-
DROME
Parikh, S.H.1, Martin, P.L.1, Prasad, V.K.1, Szabolcs, P.1,
Driscoll, T.A.1, Kurtzberg, J.1 1Duke University Medical Center,
Durham, NC.
Myelodysplastic syndromes (MDS) in children are associated
with signiﬁcant morbidity and risk of leukemic transformation.
Allogeneic hematopoietic stem cell transplantation is the only
curative therapy. The ideal allogeneic donor is an HLA-identical
sibling or relative or Matched Related Donor (MRD). From 1990
to 2005, a total of 12 pediatric or young adult patients with MDS
received bone marrow transplant from an HLA matched sibling at
our institution. M:F ratio of the study group was 1.4; One patient
belonged to ethnic minorities (8%); the median age at transplant
was 13.4 years (range 1.1-20.6) and median weight was 54.7 kg
(range 10.8-78). Three patients had therapy-related MDS (2 ALL,
1 NHL). MDS stage was RA/RC in 2 pts, RARS in 1 pt, RAEB in
5 pts, RAEB-T in 2 pts, and AML in 2 pts. Monosomy 7 was
present in 3 (25%) pts. Median time from diagnosis to transplant
was 3 months (range 1.27-56.83). Preparative regimen was non-
TBI based in 10 (83%) pts. TBI was used for the only 2 (17%) pts
with AML. Eleven (92%) patients received melphalan. Cyclospor-
ine was used for GVHD prophylaxis with methotrexate in 10 pts
and Solu-medrol in 2 pts. The grafts contained a median of 2.1 
10e8 (range 0.7-8.46) nucleated cells/kg infused. Median time to
neutrophil recovery (ANC  500) was 15 days (range 10-33), and
that to platelet recovery (50K untransfused) was 44 days (range
29-150). Acute GVHD, grade 1-2, was seen in 7 (58%) patients;
none of the patients had grade 3-4 acute GVHD. Chronic GVHD
was seen in 2 (16.6%) patients, 1 limited to skin, and 1 extensive
involving skin and gut. The only patient with RARS died from
lactic acidosis. One patient, who had undergone a prior transplant
for ALL, acquired monosomy 7 clone 40 months later. She under-
went BMT from the same donor, relapsed again after 22 months,
underwent a third successful transplant from the same donor with
non-myeloablative conditioning and peripheral blood stem cells.
She is disease free 6 years from the last transplant. Thus, 11
(91.6%) of the 12 patients are surviving long term and disease free
with a median follow-up of 6.81 years (range 1.02-16.01). Bone
marrow transplant from matched sibling donor with non-TBI
based, melphalan containing regimen is very effective in curing
MDS affecting children and young adults.
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OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME
Parikh, S.H.1, Mendizabal, A.2, Martin, P.L.1, Szabolcs, P.1,
Prasad, V.K.1, Driscoll, T.A.1, Kurtzberg, J.1 1Duke University Med-
ical Center, Durham, NC; 2Emmes Corporation, Rockville, MD.
Myelodysplastic syndromes (MDS) in children are associated
with signiﬁcant morbidity and risk of leukemic transformation.
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